RE:Covid Immunity Passport siteGreat points Trek. I was in favour of cancer investigation at the time as vCJD moved out of the public sphere with mass culls and prohibiitions on the use of animal parts as feed.
But this brings up an interesting comparison between how the company repositioned itself then and now.
Back then funding for CJD dried up and Amorfix took a hit with Biogen ending it's relationship, (what were they supporting, a blood test?) so cancer was a gamble but we needed something new and the CEO Gundel seemed to be strongly behind diversification.
This time with covid the CEO seemed indifferent, the presentations only ever listed it as an after thought, the money invested was minimal, and the JV formed moved onto an AD blood diagnostic.
As for schizophrenia, I think it's a legit target for our platform so I don't see it as diversification in the same way as cancer or covid.
“We now have tools – including ProMIS’ proprietary computational algorithms – to approach schizophrenia and related diseases for druggable misfolded protein targets,” stated Dr. Neil Cashman, ProMIS’ Chief Scientific Officer. “This represents a true confluence of opportunity for ProMIS in psychiatric diseases, just like we have accomplished for neurodegenerative diseases.”
2022 is going to be a long year of waiting for shareholders and I would hate to see Promis focus only on PMN310 to conserve cash on labwork while we seem to be top heavy with advisors and consultants and whatever other suits have been recruited to get through P1 paperwork.
There is risk either way, but I actually think the company has been managing cash well since the new investors joined.